The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAssura Regulatory News (AGR)

Share Price Information for Assura (AGR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.60
Bid: 42.48
Ask: 42.56
Change: -0.08 (-0.19%)
Spread: 0.08 (0.188%)
Open: 42.86
High: 42.86
Low: 42.10
Prev. Close: 42.68
AGR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

6 Jul 2023 07:00

RNS Number : 1029F
Assura PLC
06 July 2023
 

6 July 2023

Assura plc

 

Trading Update

For the first quarter ending 30 June 2023

 

Assura plc ("Assura"), the leading primary care property investor and developer, today announces its Trading Update for the first quarter to 30 June 2023.

 

Jonathan Murphy, CEO, said:

"Assura has delivered another quarter of strong financial performance and disciplined activity.

"Our on-site activities progressed well, with two developments and one asset enhancement project reaching practical completion, providing high quality premises and enabling an improved range of health services for patients.

"We made good progress with rent reviews over the period, settling a further 55 reviews to generate an uplift of £0.6 million.

"We continue to see many opportunities to work with the NHS in providing critical primary care infrastructure. Our leading market position, strong and sustainable financial position and pipeline of growth opportunities will allow us to continue to deliver against our proven strategy."

 

Continued strong track record of disciplined activity through first quarter

· Portfolio of 610 properties with an annualised rent roll of £145.3 million

· Two developments completed; our 100th development in Wolverhampton (as announced 29 June 2023) and our £22 million scheme in Kettering

· Completed one asset enhancement capital project (total spend £1.1 million); on site with a further nine (total spend £8.2 million)

· 55 rent reviews settled in the quarter, covering £5.5 million of existing rent and generating an uplift of £0.6 million

· Quarterly dividend increased by 5% to 0.82 pence per share, as announced at the full year results, with effect from the July 2023 payment

 

Development and asset enhancement pipelines provide growth opportunities

· Currently on site with nine developments; total cost of £103 million (March 2023: 11, £129 million) of which £45 million has been spent to date

· Immediate development pipeline of five schemes, where we would normally expect to be on site within 12 months; total cost of £35 million (March 2023: 5, £37 million). We continue to experience delays on pipeline schemes as we negotiate to ensure rents appropriately reflect the current cost of construction.

· 36 lease re-gears covering £8.4 million of existing rent roll in the current pipeline

· Pipeline of 17 capital asset enhancement projects (projected spend £11 million) over the next two years

 

Strong and sustainable financial position

· Weighted average interest rate unchanged at 2.30% (March 2023: 2.30%); all drawn debt on fixed rate basis

· Weighted average debt maturity of 6.8 years, no refinancing on drawn debt due until October 2025. Over 50% of drawn debt matures beyond 2030, with our longest maturity debt at our lowest rates

· Net debt of £1,144 million on a fully unsecured basis with cash and undrawn facilities of £234 million

 

 

- ENDS -

 

 

Assura plc Jayne Cottam, CFO David Purcell, Investor Relations Director

Tel: 01925 945354 Email: Investor@assura.co.uk

 

FGS Global

Gordon SimpsonJames Thompson

 

Tel: 0207 251 3801 Email: Assura@fgsglobal.com

 

 

Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served.

 

A constituent of the FTSE 250 and the EPRA* indices, as at 31 March 2023, Assura's portfolio was valued at £2.7 billion.

 

At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026. 

 

Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.

 

Further information is available at www.assuraplc.com

 

Assura plc LEI code: 21380026T19N2Y52XF72

 

*EPRA is a registered trademark of the European Public Real Estate Association.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFIRDTIEIIV
Date   Source Headline
16th Jan 20177:00 amRNSScrip Dividend Declaration
22nd Dec 20167:00 amRNSScrip Calculation Price
8th Dec 20167:00 amRNSNotice of Dividend
22nd Nov 20167:00 amRNSInterim Results 2016
1st Nov 20167:00 amRNSTotal Voting Rights
21st Oct 20162:37 pmRNSNotification of Major Interest in Shares
19th Oct 20169:00 amRNSNotification of Transaction by PDMR
17th Oct 20167:00 amRNSScrip Dividend Declaration
3rd Oct 20167:00 amRNSAppointment of Interim CEO and director
3rd Oct 20167:00 amRNSTrading Update
22nd Sep 20167:00 amRNSScrip Calculation Price
20th Sep 20165:14 pmRNSNotification of Major Interest in Shares
16th Sep 20163:35 pmRNSNotification of Major Interest in Shares
13th Sep 201611:05 amRNSNotification of transactions by PDMRs
8th Sep 20167:00 amRNSNotice of Dividend
1st Sep 20168:00 amRNSTotal Voting Rights
31st Aug 20164:49 pmRNSExercise of Nil Cost Options under VCP
26th Aug 201611:00 amRNSAdditional Listing
9th Aug 20168:00 amRNSDirector/PDMR Shareholdings
1st Aug 20168:00 amRNSTotal Voting Rights
29th Jul 201611:44 amRNSAnnual Information Update
27th Jul 20168:00 amRNSDirector/PDMR Shareholdings
25th Jul 20168:00 amRNSScrip Dividend Declaration
19th Jul 20164:40 pmRNSResult of AGM
19th Jul 20167:00 amRNSTrading Update
4th Jul 201611:34 amRNSGraham Roberts
30th Jun 20167:00 amRNSScrip Calculation Price
17th Jun 20169:11 amRNSPayment on cessation of directorship
16th Jun 20169:00 amRNSNotice of Dividend
15th Jun 20164:16 pmRNSAnnual Report & Notice of AGM
14th Jun 20167:00 amRNSUpdate statement regarding Graham Roberts
23rd May 20163:48 pmRNSDirector/PDMR Shareholding
18th May 20167:00 amRNSFull Year Results
6th May 20169:34 amRNSNotification of Major Interest in Shares
4th May 20169:01 amRNSTotal Voting Rights
26th Apr 201612:24 pmRNSNotification of Major Interest in Shares
20th Apr 201612:28 pmRNSNotification of Major Interest in Shares
20th Apr 20167:00 amRNSDirector/PDMR Shareholdings
18th Apr 20167:00 amRNSScrip Dividend Declaration
24th Mar 20164:25 pmRNSNotification of Major Interest in Shares
24th Mar 201612:22 pmRNSScrip calculation price
22nd Mar 20166:05 pmRNSDirector/PDMR Shareholding
22nd Mar 20163:56 pmRNSNotification of Major Interest in Shares
21st Mar 20167:00 amRNSDirector/PDMR Shareholding
15th Mar 201611:54 amRNSDirector/PDMR Shareholding
10th Mar 20167:00 amRNSNotice of Dividend
4th Mar 20167:00 amRNSFurther statement regarding Graham Roberts
29th Feb 20167:00 amRNSDirector Declaration
9th Feb 20167:05 amRNSTrading Update
9th Feb 20167:00 amRNSStatement regarding Chief Executive Graham Roberts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.